H.C. Wainwright analyst Edward White initiated coverage of Magenta Therapeutics with a Neutral rating and no price target. The company halted pipeline development and strategic alternatives are being explored, the analyst tells investors in a research note. The firm believes Magenta’s cash per share of $1.85 could offer some upside to the stock price.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MGTA:
- Magenta Therapeutics downgraded to Neutral at BTIG after MGTA-117 trial paused
- Magenta Therapeutics downgraded to Neutral from Buy at BTIG
- Wedbush downgrades Magenta Therapeutics to Neutral, lowers target to $1
- Magenta Therapeutics downgraded to Neutral from Outperform at Wedbush
- Magenta Therapeutics pauses MGTA-117 trial following Grade 5 SAE